secwatch / observer
8-K filed May 18, 2026, 4:15 PM ET ticker CLRB CIK 0001279704
leadership confidence high sentiment neutral materiality 0.55

Cellectar director Loren not standing for reelection; Nantahala analyst Gu appointed to board

Cellectar Biosciences, Inc.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Stefan D. Loren

Class III Director
CLRB · Cellectar Biosciences, Inc.
Filed
May 18, 2026, 4:15 PM ET
On May 17, 2026, Stefan D. Loren, Ph.D. notified the board of directors (the “Board”) of Cellectar Biosciences, Inc. (the “Company”), that he does not intend to stand for reelection as a Class III director at the upcoming 2026 annual meeting of the stockholders of the Company (the “Annual Meeting”), at which time his current term as a director will expire.
Appointed

Andrew Gu

Class III Director
CLRB · Cellectar Biosciences, Inc.
Effective
2026-05-18
Filed
May 18, 2026, 4:15 PM ET
On May 18, 2026, the Board appointed Mr. Gu to serve as a member of the Board as a Class III director.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Stefan D. Loren departed as Class III Director at Cellectar Biosciences, Inc..

Action
not standing for reelection
Role
Class III Director
Exact text from the filing
On May 17, 2026, Stefan D. Loren, Ph.D. notified the board of directors (the “Board”) of Cellectar Biosciences, Inc. (the “Company”), that he does not intend to stand for reelection as a Class III director at the upcoming 2026 annual meeting of the stockholders of the Company (the “Annual Meeting”), at which time his current term as a director will expire.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Andrew Gu was appointed as Class III Director at Cellectar Biosciences, Inc..

Action
appointed
Role
Class III Director
Exact text from the filing
On May 18, 2026, the Board appointed Mr. Gu to serve as a member of the Board as a Class III director.
View on SEC.gov

Cellectar Biosciences, Inc. filing history →

Source: SEC EDGAR
accession 0001104659-26-063202
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.